Sclerostin inhibition alleviates breast cancer–induced bone metastases and muscle weakness
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Breast cancer bone metastases often cause a debilitating non-curable condition with osteolytic lesions, muscle weakness and a high mortality. Current treatment comprises chemotherapy, irradiation, surgery and anti-resorptive drugs that restrict but do not revert bone destruction. In metastatic breast cancer cells, we determined the expression of sclerostin, a soluble Wnt inhibitor that represses osteoblast differentiation and bone formation. In mice with breast cancer bone metastases, pharmacological inhibition of sclerostin using an anti-sclerostin antibody (Scl-Ab) reduced metastases without tumor cell dissemination to other distant sites. Sclerostin inhibition prevented the cancer-induced bone destruction by augmenting osteoblast-mediated bone formation and reducing osteoclast-dependent bone resorption. During advanced disease, NF-κB and p38 signaling was increased in muscles in a TGF-β1-dependent manner, causing muscle fiber atrophy, muscle weakness and tissue regeneration with an increase in Pax7-positive satellite cells. Scl-Ab treatment restored NF-κB and p38 signaling, the abundance of Pax7-positive cells and ultimately muscle function. These effects improved the overall health condition and expanded the life span of cancer-bearing mice. Together, these results demonstrate that pharmacological inhibition of sclerostin reduces bone metastatic burden and muscle weakness with a prolongation of the survival time. This might provide novel options for treating musculoskeletal complications in breast cancer patients. .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dempster, D. W., Compston, J. E., Drezner, M. K., Glorieux, F. H., Kanis, J. A., Malluche, H., Meunier, P. J., Ott, S. M., Recker, R. R., & Parfitt, A. M. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1805 · Cited by 2,543
WNT signaling in bone homeostasis and disease: From human mutations to treatments
Baron, R., & Kneissel, M. (2013) · Nature Medicine · doi:10.1038/nm.3074 · Cited by 2,093 · cited 3×
“Sclerostin is a soluble Wnt antagonist that prevents binding of Wnt ligands to Lrp5/6 and therefore the activation of the pathway and ultimately osteoblast-mediated bone formation (11).”
BackgroundInfluentialRomosozumab Treatment in Postmenopausal Women with Osteoporosis
Cosman, F., Crittenden, D. B., Adachi, J. D., Binkley, N., Czerwinski, E., Ferrari, S., Hofbauer, L. C., Lau, E., Lewiecki, E. M., Miyauchi, A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607948 · Cited by 1,805 · cited 4×
“In clinical trials, treatment of women with postmenopausal osteoporosis with Scl-Ab (romosozumab; Evenity, Amgen/UCB) increased bone formation, while bone resorption was decreased, leading to an increase in BMD and a reduction of the fracture rate at several sites, including the hip and spine (13, 14).”
ResultInfluentialBaracos, V. E., Martin, L., Korc, M., Guttridge, D. C., & Fearon, K. C. H. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.105 · Cited by 1,738 · cited 1×
“Patients with advanced metastatic breast cancer often experience a wasting condition in which skeletal muscle undergoes atrophy, leading to pronounced weight loss and ultimately cachexia (39, 40).”
BackgroundHigh Bone Density Due to a Mutation in LDL-Receptor–Related Protein 5
Boyden, L. M., Mao, J., Belsky, J., Mitzner, L., Farhi, A., Mitnick, M. A., Wu, D., Insogna, K., & Lifton, R. P. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013444 · Cited by 1,591
Little, R. D., Folz, C., Manning, S. P., Swain, P. M., Zhao, S.-C., Eustace, B., Lappe, M. M., Spitzer, L., Zweier, S., Braunschweiger, K., et al. (2002) · The American Journal of Human Genetics · doi:10.1086/338450 · Cited by 1,282
Romosozumab in Postmenopausal Women with Low Bone Mineral Density
McClung, M. R., Grauer, A., Boonen, S., Bolognese, M. A., Brown, J. P., Diez-Perez, A., Langdahl, B. L., Reginster, J.-Y., Zanchetta, J. R., Wasserman, S. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1305224 · Cited by 1,258
Pax7-expressing satellite cells are indispensable for adult skeletal muscle regeneration
Sambasivan, R., Yao, R., Kissenpfennig, A., Van Wittenberghe, L., Paldi, A., Gayraud-Morel, B., Guenou, H., Malissen, B., Tajbakhsh, S., & Galy, A. (2011) · Development · doi:10.1242/dev.067587 · Cited by 939 · cited 1×
“In the muscle microenvironment, Pax7-positive satellite cells are the main resident stem cells that can give rise to myocytes (41).”
BackgroundSclerostin Stimulates Osteocyte Support of Osteoclast Activity by a RANKL-Dependent Pathway
Wijenayaka, A. R., Kogawa, M., Lim, H. P., Bonewald, L. F., Findlay, D. M., & Atkins, G. J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025900 · Cited by 503 · cited 1×
“as a decoy receptor to RANKL and decreases the RANKL/OPG ratio and bone resorption (38).”
BackgroundNF-κB–mediated Pax7 dysregulation in the muscle microenvironment promotes cancer cachexia
He, W. A., Berardi, E., Cardillo, V. M., Acharyya, S., Aulino, P., Thomas-Ahner, J., Wang, J., Bloomston, M., Muscarella, P., Nau, P., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68523 · Cited by 357 · cited 2×
“This mechanism blocks myogenic differentiation and myoblast fusion and promotes muscle wasting (29).”
Background
Cited by
The dormant cancer cell life cycle
Phan, T. G., & Croucher, P. I. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0263-0 · Cited by 576
Coleman, R. E., Croucher, P. I., Padhani, A. R., Clézardin, P., Chow, E., Fallon, M., Guise, T., Colangeli, S., Capanna, R., & Costa, L. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00216-3 · Cited by 570
Bone metastasis: mechanisms, therapies, and biomarkers
Clézardin, P., Coleman, R., Puppo, M., Ottewell, P., Bonnelye, E., Paycha, F., Confavreux, C. B., & Holen, I. (2021) · Physiological Reviews · doi:10.1152/physrev.00012.2019 · Cited by 416
The osteocyte as a signaling cell
Delgado-Calle, J., & Bellido, T. (2022) · Physiological Reviews · doi:10.1152/physrev.00043.2020 · Cited by 261
Bone-muscle crosstalk under physiological and pathological conditions
Dong, Y., Yuan, H., Ma, G., & Cao, H. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05331-y · Cited by 52
“On the other hand, TGFβ1 causes muscle fiber atrophy through Nuclear factor κB (NF-κB) and p38 signal - ing, and increases Pax7-positive satellite cells, which can be reversed by SCL neutralizing antibody [119].”
Background
Metadata
- Authors
- Hesse, E., Schröder, S., Brandt, D., Pamperin, J., Saito, H., & Taipaleenmäki, H.
- Venue
- JCI Insight
- Published
- 2019-05-02
- Volume
- 4
- Issue
- 9
- ISSN
- 2379-3708 (ISSN-L)
- OpenAlex
- W2937633108
- Cited by
- 115
- References
- 11
- FWCI
- 5.89
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sclerostin inhibition alleviates breast cancer–induced bone metastases and muscle weakness. https://app.cochat.ai/papers/10.1172/jci.insight.125543
- The paper
- Hesse, E., Schröder, S., Brandt, D., Pamperin, J., Saito, H., & Taipaleenmäki, H. (2019). Sclerostin inhibition alleviates breast cancer–induced bone metastases and muscle weakness. JCI Insight. https://doi.org/10.1172/jci.insight.125543
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.